SEC Form SC 13G filed by Exelixis Inc.

2/13/24 9:19:48 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EXEL alert in real time by email

SC 13G 1 exel-13g_20231231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EXELIXIS, INC. ---------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 Par Value per Share ---------------------------------------------------------------------------- (Title of Class of Securities) 30161Q104 ---------------------------------------------------------------------------- (CUSIP Number) December 19, 2023 ---------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 30161Q104 13G Page 2 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Renaissance Technologies LLC 26-0385758 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 15,615,716 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 15,615,716 _____________________________ (8) SHARED DISPOSITIVE POWER 0 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,615,716 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.16 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Page 2 of 8 pages ============================================================================= Page 3 of 8 pages ----------------------------------------------------------------------------- CUSIP NO. 30161Q104 13G Page 3 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 15,615,716 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 15,615,716 _____________________________ (8) SHARED DISPOSITIVE POWER 0 _____________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,615,716 ----------------------------------------------------------------------------- (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ----------------------------------------------------------------------------- (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.16 % ----------------------------------------------------------------------------- (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC Page 3 of 8 pages ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 30161Q104 13G Page 4 of 8 Pages ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer EXELIXIS, INC. (b) Address of Issuer's Principal Executive Offices. 1851 Harbor Bay Parkway, Alameda, CA 94502 Item 2. (a) Name of Person Filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"). (b) Address of Principal Business Office or, if none, Residence. The principal business address of the reporting persons is: 800 Third Avenue New York, New York 10022 (c) Citizenship. RTC is a Delaware limited liability company, and RTHC is a Delaware corporation. (d) Title of Class of Securities. Common Stock, $.001 Par Value per Share (e) CUSIP Number. 30161Q104 Page 4 of 8 pages ============================================================================= Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. RTC: 15,615,716 shares RTHC: 15,615,716 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC. (b) Percent of Class. RTC: 5.16 % RTHC: 5.16 % (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: RTC: 15,615,716 RTHC: 15,615,716 (ii) Shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: RTC: 15,615,716 RTHC: 15,615,716 (iv) Shared power to dispose or to direct the disposition of: RTC: 0 RTHC: 0 Page 5 of 8 pages ============================================================================= Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [_] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Page 6 of 8 pages ============================================================================= Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 Renaissance Technologies LLC By: /s/ Brian Felczak Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 7 of 8 Pages ============================================================================== EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING UNDER RULE 13D-1(K) OF THE EXCHANGE ACT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, $.001 Par Value per Share of EXELIXIS, INC. Date: February 13, 2024 Renaissance Technologies LLC By: /s/ Brian Felczak Chief Financial Officer Renaissance Technologies Holdings Corporation By: /s/ Brian Felczak Vice President Page 8 of 8 Pages

Get the next $EXEL alert in real time by email

Recent Analyst Ratings for

$EXEL

Date	Price Target	Rating	Analyst
2/24/2025	$36.00	Overweight → Equal Weight	Wells Fargo
1/27/2025	$30.00 → $40.00	Equal-Weight → Overweight	Morgan Stanley
1/24/2025		Outperform → Perform	Oppenheimer
12/20/2024	$36.00 → $40.00	Outperform → Market Perform	BMO Capital Markets
12/17/2024	$35.00 → $39.00	Buy → Neutral	BofA Securities
10/16/2024	$30.00 → $34.00	Outperform	RBC Capital Mkts
9/19/2024	$30.00	Neutral	UBS
4/11/2024	$25.00	Overweight → Equal Weight	Barclays

More analyst ratings

SEC Form SC 13G filed by Exelixis Inc.

Chat with this insight

Recent Analyst Ratings for $EXEL

$EXEL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

$EXEL SEC Filings

Exelixis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 144 filed by Exelixis Inc.

SEC Form 144 filed by Exelixis Inc.

$EXEL Press Releases

Fastest customizable press release news feed in the world

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

$EXEL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Exelixis downgraded by Wells Fargo with a new price target

Exelixis upgraded by Morgan Stanley with a new price target

Exelixis downgraded by Oppenheimer

$EXEL FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for CABOMETYX issued to EXELIXIS INC

FDA Approval for CABOMETYX issued to EXELIXIS INC

FDA Approval for CABOMETYX issued to EXELIXIS INC

$EXEL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Eckhardt Sue Gail sold $805,140 worth of shares (18,838 units at $42.74), decreasing direct ownership by 47% to 21,380 units (SEC Form 4)

Director Wyszomierski Jack L sold $324,683 worth of shares (7,535 units at $43.09), decreasing direct ownership by 2% to 358,882 units (SEC Form 4)

SEC Form 4 filed by Director Johnson David Edward

$EXEL Financials

Live finance-specific insights

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

$EXEL Leadership Updates

Live Leadership Updates

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

$EXEL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

SEC Form SC 13G filed by Exelixis Inc.

SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

Recent Analyst Ratings for
$EXEL

$EXEL
Insider Purchases

$EXEL
SEC Filings

$EXEL
Press Releases

$EXEL
Analyst Ratings

$EXEL
FDA approvals

$EXEL
Insider Trading

$EXEL
Financials

$EXEL
Leadership Updates

$EXEL
Large Ownership Changes